|Mr. John Rodney Varner||Co, Founder, Pres, CEO, Sec. & Chairman||750.94k||N/A||1957|
|Mr. Ryan M. Confer M.S.||Chief Financial Officer||522.53k||N/A||1982|
|Ms. Catherine M. Vaczy||Exec. VP, Gen. Counsel & Chief Strategy Officer||646.02k||N/A||1961|
|Mr. Michael T. Redman||Exec. VP & COO||N/A||N/A||1955|
|Ms. Kalyn Dabbs||Sr. Mang. of Communications & Marketing||N/A||N/A||N/A|
|Mr. Thomas C. Gallagher Esq.||Sr. VP of Intellectual Property & Licensing||N/A||N/A||N/A|
|Dr. William E. Gannon Jr.||Member of Clinical Advisory Board & VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Jack A. Roth F.A.C.S., FACS, M.D.||Chairman of Scientific & Medical Advisory Board||N/A||N/A||N/A|
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 10.